Insight

May 24, 2024, 13:24

Erman Akkus Summarizes 5-year Results of CheckMate 040

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“Nivolumab plus ipilimumab after sorafenib in patients with advanced HCC
5-year results of CheckMate 040
Annals of Oncology

Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W (four doses), followed by nivolumab 240 mg Q2W

ORR: 34%
mDOR: 51.2 mo
mOS: 22.2 mo
60-month OS rate: 29%″

Erman Akkus

Read the article.
Source: Erman Akkus/X
.

5-year results advanced HCC Annals of Oncology cancer cancer therapy cancer treatment CheckMate 040 clinical trial Erman Akkus Healthcare Research hepatocellular carcinoma immunotherapy ipilimumab mDoR median duration of response median overall survival mOS nivolumab objective response rate OncoDaily Oncology oncology research ORR Research sorafenib survival rates

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Special Coverage